Two Schedules of Teniposide with or Without Cisplatin in Advanced Non-Small-Cell Lung Cancer: A Randomized Study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group

Journal of Clinical Oncology

Volumn 14, Issue 1, 1996, Pages 127-134

  Splinter, Ted A W ^b   Sahmoud, Tarek ^b   Festen, Jan ^b   Van Zandwijk, Nico ^b   Sörenson, Sverre ^b   Clerico, Mario ^b   Burghouts, Jos ^b   Dautzenberg, Bertrand ^b   Kho, Gwan S ^b   Kirkpatrick, Anne ^b   Giaccone, Giuseppe ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; ETOPOSIDE; TENIPOSIDE;

ADULT; ADVANCED CANCER; AGED; ALLERGIC REACTION; ALOPECIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; FEMALE; HUMAN; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; OTOTOXICITY; PHLEBITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STOMATITIS; VOMITING;

ADULT; AGED; ALOPECIA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DIARRHEA; DISEASE-FREE SURVIVAL; DNA TOPOISOMERASES, TYPE II; FACTOR ANALYSIS, STATISTICAL; FEMALE; HEMATOLOGIC DISEASES; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PERIPHERAL NERVOUS SYSTEM DISEASES; PROPORTIONAL HAZARDS MODELS; SURVIVAL RATE; TENIPOSIDE;

EID: 0030048760     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1996.14.1.127     Document Type: Article

References (30)

1. Ginsberg RJ, Kris MG, Armstrong JG: Cancer of the lung. Non-small cell lung cancer, in DeVita VT, Hellman S, Rosenberg SA (eds): Cancer: Principles and Practice of Oncology (ed 4). Philadelphia, PA, Lippincott, 1993, pp 673-722
2. Ruckdeschel JC, Finkelstein DM, Ettinger DS, et al: A randomized trial of the four most active regimens for metastatic non-small-cell lung cancer. J Clin Oncol 4:14-22, 1986
3. Bonomi PD, Finkelstein DM, Ruckdeschel JC, et al: Combination chemotherapy versus single agents followed by combination chemotherapy in stage IV non-small-cell lung cancer: A study of the Eastern Cooperative Oncology Group. J Clin Oncol 7:1602-1613, 1989
4. Weick JK, Crowley J, Natale RB, et al: A randomized trial of five cisplatin-containing treatments in patients with metastatic non-small-cell lung cancer: A Southwest Oncology Group study. J Clin Oncol 9:1157-1162, 1991
5. Albain KS, Crowley JJ, LeBlanc M, et al: Survival determinants in extensive-stage non-small-cell lung cancer: The Southwest Oncology Group experience. J Clin Oncol 9:1618-1626, 1991
6. Klastersky J, Sculier JP, Bureau G, et al: Cisplatin versus cisplatin plus etoposide in the treatment of advanced non-small-cell lung cancer. J Clin Oncol 7:1087-1092, 1989
7. Schabel FM, Trader MW, Laster WR, et al: Cis-dichlorodiaammineplatinum (II): Combination chemotherapy and cross-resistance studies with tumors of mice. Cancer Treat Rep 63:1459-1473, 1979
8. Tsai C-M, Gazdar AF, Venzon DJ, et al: Lack of in vitro synergy between etoposide and cis-diamminedichloroplatinum (II). Cancer Res 49:2390-2397, 1989
9. O'Dwyer PJ, Alonso MT, Leyland-Jones B, et al: Teniposide: A review of 12 years and experience. Cancer Treat Rep 68:1455-1466, 1984
10. D'Incalci M, Rossi C, Sessa C, et al: Pharmacokinetics of teniposide in patients with ovarian cancer. Cancer Treat Rep 69:73-77, 1985
11. Colombo M, Broggini M, Vaghi M, et al: Comparison between VP16 and VM26 in Lewis lung carcinoma of the mucosa. Eur J Cancer Clin Oncol 22:173-179, 1986
12. Bork E, Hansen M, Dombernowsky P, et al: Teniposide (VM26), an overlooked highly active agent in small-cell lung cancer. Results of a phase II trial in untreated patients. J Clin Oncol 4:524-527, 1986
13. Giaccone G, Donadio M, Ferrati P, et al: Teniposide (VM26) in the treatment of non-small cell lung carcinoma. Cancer Treat Rep 71:83-85, 1987
14. Iberti V, Donadio M, Giaccone G: Cisplatin and teniposide chemotherapy for advanced non-small cell lung cancer. Eur J Cancer 27:1104-1106, 1991
15. Cavalli P, Sonntag RW, Jungi F, et al: VP16-213 monotherapy for remission induction of small cell lung cancer. A randomized trial using three dosage schedules. Cancer Treat Rep 62:473-475, 1978
16. Slevin ML, Clark PI, Joel SP, et al: A randomized trial to evaluate the effect of schedule on the activity of etoposide in small cell lung cancer. J Clin Oncol 7:1333-1340, 1989
17. Pocock SJ, Simon R: Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics 31:103-115, 1975
18. World Health Organization: Handbook of reporting results of cancer treatment. Offset publication no. 48. Geneva, Switzerland, World Health Organization, 1979
19. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
20. Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50:163-170, 1966
21. Cox DR: Regression models and life-tables. J R Stat Soc B34:187-202, 1972
22. Breslow N: Comparison of survival curves, in Buyse ME, Staquet MJ, Sylvester RJ (eds): Cancer Clinical Trials Methods and Practice. Oxford, United Kingdom, Oxford Medical, 1988, pp 382-406
23. Mantel N, Haenszel W: Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22:719-748, 1959
24. Rosso R, Salvati F, Ardizzoni A, et al: Etoposide versus etoposide plus high-dose cisplatin in the management of advanced non-small cell lung cancer. Cancer 66:130-134, 1990
25. Elliott JA, Ahmedzai S, Hole D, et al: Vindesine and cisplatin combination chemotherapy compared with vindesine as a single agent in the management of non-small cell lung cancer: A randomized study. Eur J Cancer Clin Oncol 20:1025-1032, 1984
26. Einhorn LH, Loehrer PJ, Williams SD, et al: Random prospective study of vindesine versus vindesine plus high-dose cisplatin versus vindesine plus cisplatin plus mitomycin C in advanced non-small cell lung cancer. J Clin Oncol 4:1037-1043, 1986
27. Luedke DW, Einhorn L, Omura GA, et al: Randomized comparison of two combination regimens versus minimal chemotherapy in non-small-cell lung cancer: A Southeastern Cancer Study Group trial. J Clin Oncol 8:886-891, 1990
28. LeChevalier T, Brisgand D, Douillard J-Y, et al: Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: Results of a European multicenter trial including 612 patients. J Clin Oncol 12:360-367, 1994
29. Liu LF: DNA topoisomerase poisons as antitumor drugs. Annu Rev Biochem 58:351-375, 1989
30. Lilenbaum RC, Green MR: Novel chemotherapeutic agents in the treatment of non-small-cell lung cancer. J Clin Oncol 11:1391-1402, 1993